Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price fell 18.2% during trading on Thursday . The stock traded as low as C$0.18 and last traded at C$0.18. 7,500 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 18,857 shares. The stock had previously closed at C$0.22.
Devonian Health Group Price Performance
The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The firm’s 50-day moving average price is C$0.22 and its two-hundred day moving average price is C$0.18. The stock has a market cap of C$26.68 million, a PE ratio of -9.00 and a beta of 1.28.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- Investing In Automotive Stocks
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
